×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
SESSION 5: REGULATORY PRACTICES ADDRESSING SCIENTIFIC AND THERAPEUTIC INNOVATION
Session Chair(s)
Inas Chehimi
Executive Director - Regulatory & Policy Head - MEA
Novartis Pharma Services AG, United Arab Emirates
Reviewing some of the paradigm shifts in technical research and development; “How changes in the scientific understanding of disease are influencing changes in regulatory pathways”.
Speaker(s)
Introduction
Trevor M. Jones, CBE
King's College London, United Kingdom
former Director General ABPI
Regulatory Pathway / Share Experience
Balazs Sarkadi
Hungarian Academy of Sciences, Research Centre For Natrual Sciences, Hungary
Head of Biomembrane Research Group
Ramy Behbehani, MS
Kuwait Drug & Food Control Adminstration Kuwait, Kuwait
Drug Registration and Release Superintendent
Industry R&D Overview / FDA Regulatory Pathways and EU Industry
Mikkel Oestergaard, PhD
Roche Products Limited, Switzerland
Epidemiologist
Have an account?